Comorbidity of Fibromyalgia and Psychiatric Disorders

Arnold, Lesley M.; Hudson, James I.; Keck, Paul E.; Auchenbach, Megan B.; Javaras, Kristin N.; Hess, Evelyn V.

doi:10.4088/jcp.v67n0807

Cited by 321 publications

(225 citation statements)

References 0 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…The vast majority of patients (Ͼ95%) were female, reflecting the higher prevalence of both fibromyalgia and depression in women in the general population and in clinical studies (6)(7)(8)20) The high mean body weight (Ͼ81 kg) at baseline is reflective of clinical samples of depressed patients with and those without comorbid fibromyalgia (8,27). The majority of patients were moderately to severely depressed, with a mean HAM-D score at baseline of 24.8; most had a recurrent course of illness, with nearly half (48%) reporting 2-5 lifetime episodes and a further 24% reporting Ն6 episodes.…”

Section: Discussionmentioning

confidence: 99%

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

McIntyre

Paisley

Kouassi

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. Fibromyalgia and major depressive disorder (MDD) frequently co-occur. Quetiapine fumarate extended-release (quetiapine XR) has demonstrated efficacy in the treatment of MDD and has been shown to have analgesic properties in patients with depression. The primary objectives of this study were to evaluate the effects of quetiapine XR on depressive and pain symptoms in patients with MDD and comorbid fibromyalgia, and to assess its safety and tolerability. Results. The mean change in the HAM-D score from baseline to week 8 was significantly greater in the quetiapine XR group compared with the placebo group (؊10.0 versus ؊5.8; P ‫؍‬ 0.001). Improvements in most secondary outcomes were also significantly greater in the quetiapine XR group. Quetiapine XR was generally well tolerated.Conclusion. This study is the first to demonstrate that measures of depression, pain, and quality of life are significantly improved with quetiapine XR compared with placebo in patients with a dual diagnosis of MDD and fibromyalgia.Fibromyalgia is a syndrome characterized by widespread musculoskeletal pain that lasts at least 3 months, with a reduced pain threshold. Widespread pain is the defining feature of fibromyalgia. Associated symptoms include fatigue, sleep disturbance, stiffness, cognitive symptoms, and mood abnormalities including depression and anxiety (1,2). Pain, fatigue, and sleep disturbance are present in at least 75% of patients (3). The condition is estimated to occur in ϳ2-4% of the general adult population (4,5), and the prevalence is higher among women (4.9%) than men (1.6%) (6).Patients with fibromyalgia are at increased risk of mood disorders. Studies suggest that the prevalence of current depression among patients with fibromyalgia is as high as 22-40% (7), and that lifetime prevalence rates reach 58-86% (8,9). This high degree of co-occurrence is thought to be related in part to pathophysiologic abnormalities that are shared between fibroClinicalTrials.gov identifier: NCT00675896.

show abstract

Section: Discussionmentioning

confidence: 99%

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

McIntyre

Paisley

Kouassi

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…It is known that FM is accompanied by many psychiatric disorders including major depression, anxiety disorders and somatoform disorders (6,7). Some authors classify FM in "affective spectrum disorders", which includes diseases such as major depressive disorder, anxiety disorders, premenstrual dysphoric disorder, irritable bowel syndrome, and migraine, because of similar pathophysiological mechanisms, increased frequency of depressive symptoms, elevated comorbidity, and good response to antidepressant therapy (8,9).…”

Section: Introductionmentioning

confidence: 99%

The relationship of childhood trauma, dissociative experiences and depression with pain in female patients with fibromyalgia: a cross-sectional study

Karaş¹,

Yıldırım²,

Küçükgöncü³

et al. 2017

Dusunen Adam

View full text Add to dashboard Cite

The relationship of childhood trauma, dissociative experiences and depression with pain in female patients with fibromyalgia: a cross-sectional studyObjective: The aim of this study was to investigate childhood trauma (CT) and dissociative symptoms in patients with fibromyalgia and evaluate the relationship of these characteristics with pain intensity. Methods: Forty patients followed up with fibromyalgia diagnosis in the physical therapy and rehabilitation outpatient clinic; and as a control group, 38 healthy individuals who have similar age, gender, and educational status, were included in the study. A sociodemographic and clinical data form, Beck Depression Inventory (BDI), Childhood Trauma Questionnaire (CTQ), Dissociative Experiences Scale (DES), Somatoform Dissociation Questionnaire (SDQ) and Visual Analogue Scale (VAS) were administered to participants. Results: Emotional abuse, physical neglect, physical abuse, CTQ total, SDQ and DES scores were found to be significantly higher in the fibromyalgia group than the control group. Only the difference for SDQ scores remained significant when a comparison made between groups by controlling depression levels. Somatoform dissociation scores were found to be a significant predictor of pain intensity in patients with fibromyalgia. Conclusion: Somatoform dissociative symptoms are found to be higher in patients with fibromyalgia than the control group. These symptoms may contribute to development and exacerbation of pain in fibromyalgia. Taking the dissociative symptoms into account have an important role in the treatment of patients with fibromyalgia who have a frequent history of CT, so the treatment of these patients should be carried out in cooperation with psychiatrists. Keywords: Childhood trauma, dissociation, fibromyalgia, somatoform dissociation ÖZET Kadın fibromiyalji hastalarında çocukluk çağı travmaları, disosiyatif yaşantılar ve depresyonun ağrı ile ilişkisi: Kesitsel bir çalışma Amaç: Bu çalışmanın amacı fibromiyalji (FM) hastalarında çocukluk çağı travmaları ile disosiyatif belirtileri araştırmak ve bu özelliklerin FM'deki ağrı şiddeti ile ilişkisini incelemektir. Yöntem: Fizik tedavi ve rehabilitasyon polikliniğinde fibromyalji tanısıyla takip edilmekte olan 40 hasta ile kontrol grubu olarak yaş, cinsiyet ve öğrenim durumu açısından benzer olan 38 sağlıklı kişi çalışmaya dahil edildi. Katılımcılara sosyodemografik ve klinik veri toplama formu, Beck Depresyon Ölçeği (BDÖ), Çocukluk Çağı Travmaları Ölçeği (ÇÇTÖ), Disosiyatif Yaşantılar Ölçeği (DYÖ), Somatoform Disosiyasyon Ölçeği (SDÖ) ve Görsel Analog Skala (GAS) uygulandı. Bulgular: FM grubunda duygusal istismar, fiziksel ihmal, fiziksel istismar, ÇÇTÖ toplam, SDÖ ve DYÖ puan ortalamaları kontrol grubuna göre anlamlı derecede yüksek bulundu. Gruplar arasında depresyon düzeyleri kontrol edilerek karşılaştırma yapıldığında ise sadece SDÖ puan farklılığının anlamlı olarak devam ettiği görüldü. Somatoform disosiyasyon puanlarının FM hastalarında ağrı şiddetinin anlamlı belirleyicisi olduğu saptan...

show abstract

“…It is characterized not only by a widespread pain observed due to the presence of multiple tender points but also by depressive behavior, fatigue and sleep disturbances without any structural or inlammatory cause [125,126]. Studies have consistently demonstrated a female predominance of this disease [127] with a major frequency in pre-and postmenopause condition supporting that an abrupt decline or a reduced time of exposure to ovarian hormones may contribute to FM [128].…”

Section: Comorbidity In Menopause and Alternative Medicinementioning

confidence: 99%

Use of Phytoestrogens for the Treatment of Psychiatric Symptoms Associated with Menopause Transition

Estrada‐Camarena¹,

López‐Rubalcava²,

Sustaita³

et al. 2017

A Multidisciplinary Look at Menopause

View full text Add to dashboard Cite

Menopause transition is recognized as a vulnerable period in women life to develop or aggravate symptoms of psychiatric disorders. Several treatments including antidepressants and hormonal restitution with estrogens have been suggested to ameliorate the symptoms. Also, in this period of life is frequent the use of other drugs to treat is also frequent the use of other drugs to treat comorbid pathologies that might even increase the risk of drug-drug interactions. Literature reports that some phytochemicals with estrogenic activity have beneicial efects during menopausal transition without collateral events. This chapter shows evidence about the use of phytoestrogens as an alternative therapy for the treatment of some psychiatric symptoms associated with the menopausal transition. Data derived from preclinical research related to the use of classical phytoestrogens (isolavones), considering the beneicial efects, as well as adverse events, are discussed. Also, the use of polyphenols and organosulfurate compounds as an alternative for the treatment of anxiety-and depressive-like behavior as well as ibromyalgia is included. A narrative review was conducted using bibliography reporting the use of isolavones (genistein, daidzein, equol), coumestans or lignans for the reduction of depressive-like or anxiety-like behavior. Furthermore, it is described if the use of this compounds impact in other signs of menopause, i.e. vasomotor and osteoporosis. In addition, due to the high frequency of comorbid pathologies as diabetes mellitus, dyslipidemia or metabolic syndrome with psychiatric disorders, the use of these phytochemicals is discussed.

show abstract

Comorbidity of Fibromyalgia and Psychiatric Disorders

Cited by 321 publications

References 0 publications

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

The relationship of childhood trauma, dissociative experiences and depression with pain in female patients with fibromyalgia: a cross-sectional study

Use of Phytoestrogens for the Treatment of Psychiatric Symptoms Associated with Menopause Transition

Contact Info

Product

Resources

About